STAAR Surgical (NASDAQ:STAA – Get Free Report) major shareholder Broadwood Partners, L.P. acquired 8,221 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were bought at an average price of $21.50 per share, for a total transaction of $176,751.50. Following the transaction, the insider now owns 10,878,007 shares of the company’s stock, valued at $233,877,150.50. This trade represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Broadwood Partners, L.P. also recently made the following trade(s):
- On Tuesday, January 14th, Broadwood Partners, L.P. bought 21,155 shares of STAAR Surgical stock. The shares were bought at an average price of $21.46 per share, with a total value of $453,986.30.
- On Wednesday, December 18th, Broadwood Partners, L.P. purchased 23,000 shares of STAAR Surgical stock. The stock was purchased at an average price of $24.33 per share, for a total transaction of $559,590.00.
- On Monday, December 16th, Broadwood Partners, L.P. acquired 53,500 shares of STAAR Surgical stock. The shares were purchased at an average price of $24.24 per share, with a total value of $1,296,840.00.
STAAR Surgical Trading Up 0.6 %
Shares of STAA traded up $0.14 during trading hours on Thursday, reaching $21.85. 531,485 shares of the stock traded hands, compared to its average volume of 732,698. The company has a market cap of $1.08 billion, a P/E ratio of 49.66 and a beta of 0.63. The company’s 50-day moving average price is $25.72 and its two-hundred day moving average price is $32.16. STAAR Surgical has a 52-week low of $21.13 and a 52-week high of $52.68.
Hedge Funds Weigh In On STAAR Surgical
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the stock. Canaccord Genuity Group reduced their price target on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research report on Monday, December 9th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, January 7th. Finally, Stephens upgraded shares of STAAR Surgical to a “hold” rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $42.83.
Get Our Latest Analysis on STAA
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
See Also
- Five stocks we like better than STAAR Surgical
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- How to Choose Top Rated Stocks
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- How Investors Can Find the Best Cheap Dividend Stocks
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.